Apellis granted fast-track process for its signature treatment

Apellis Pharmaceuticals Inc. has gotten a thumbs up that will accelerate bringing one of its signature treatments to market. The U.S. Food and Drug Administration granted Fast Track status to Crestwood, Ky.-based Apellis' synthetic peptide APL-2 for the treatment of geographic atrophy (GA), an advanced form of age-related macular degeneration. Cedric Francois, Apellis' founder and CEO, said in a news release that the designation by the FDA is an important recognition that shows the drug's importance,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news